See more : Coherent, Inc. (0LHO.L) Income Statement Analysis – Financial Results
Complete financial analysis of ZimVie Inc. (ZIMV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ZimVie Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- SOL Global Investments Corp. (SOLCF) Income Statement Analysis – Financial Results
- Entain Plc (GMVHY) Income Statement Analysis – Financial Results
- Tubacex, S.A. (0KD1.L) Income Statement Analysis – Financial Results
- Universal Star (Holdings) Limited (2346.HK) Income Statement Analysis – Financial Results
- Shenzhen Sea Star Technology Co., Ltd. (002137.SZ) Income Statement Analysis – Financial Results
ZimVie Inc. (ZIMV)
About ZimVie Inc.
ZimVie Inc., a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies. The company also provides MIS solutions, such as Vital MIS and Timberline; and motion preservation solutions, including Mobi-C and The Tether. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 457.43M | 913.86M | 1.01B | 912.40M | 1.06B | 1.10B |
| Cost of Revenue | 167.05M | 300.79M | 385.80M | 312.90M | 333.90M | 382.70M |
| Gross Profit | 290.38M | 613.08M | 628.80M | 599.50M | 721.60M | 716.40M |
| Gross Profit Ratio | 63.48% | 67.09% | 61.98% | 65.71% | 68.37% | 65.18% |
| Research & Development | 26.16M | 62.69M | 61.30M | 49.20M | 55.60M | 52.30M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 248.96M | 523.97M | 554.40M | 533.50M | 605.40M | 599.90M |
| Other Expenses | 46.20M | 80.87M | 86.20M | 85.50M | 83.40M | -600.00K |
| Operating Expenses | 321.32M | 667.53M | 701.90M | 668.20M | 744.40M | 747.40M |
| Cost & Expenses | 488.37M | 968.31M | 1.09B | 981.10M | 1.08B | 1.13B |
| Interest Income | 0.00 | 18.28M | 292.00K | 302.00K | 100.00K | 0.00 |
| Interest Expense | 20.23M | 18.28M | 300.00K | 300.00K | 100.00K | 100.00K |
| Depreciation & Amortization | 121.69M | 122.79M | 129.70M | 134.30M | 135.10M | 147.70M |
| EBITDA | 91.07M | 79.16M | 28.70M | -86.70M | 107.50M | -326.40M |
| EBITDA Ratio | 19.91% | 7.87% | 5.53% | 7.37% | 10.66% | 10.56% |
| Operating Income | -30.94M | -50.85M | -73.60M | -67.10M | -22.60M | -473.50M |
| Operating Income Ratio | -6.76% | -5.56% | -7.25% | -7.35% | -2.14% | -43.08% |
| Total Other Income/Expenses | -19.91M | -8.01M | -123.12M | 1.31M | 100.00K | -700.00K |
| Income Before Tax | -50.85M | -109.92M | -101.30M | -221.30M | -27.70M | -474.20M |
| Income Before Tax Ratio | -11.12% | -12.03% | -9.98% | -24.25% | -2.62% | -43.14% |
| Income Tax Expense | 5.20M | -46.04M | -6.00M | -42.30M | 200.00K | -14.80M |
| Net Income | -393.28M | -63.88M | -95.30M | -179.00M | -27.90M | -460.40M |
| Net Income Ratio | -85.98% | -6.99% | -9.39% | -19.62% | -2.64% | -41.89% |
| EPS | -14.87 | -2.45 | -3.65 | -6.86 | -1.07 | -17.64 |
| EPS Diluted | -14.87 | -2.45 | -3.65 | -6.86 | -1.07 | -17.64 |
| Weighted Avg Shares Out | 26.45M | 26.08M | 26.10M | 26.10M | 26.10M | 26.10M |
| Weighted Avg Shares Out (Dil) | 26.45M | 26.08M | 26.10M | 26.10M | 26.10M | 26.10M |
ZimVie Inc. (ZIMV) Q3 2024 Earnings Call Transcript
ZimVie to Report Third Quarter Financial Results on October 30, 2024
Mexico Spinal Implants Market Size, Share & Trends Analysis 2024-2030, with Focus on Market Leaders ZimVie/Highridge Medical, Medtronic and DePuy Synthes
ZimVie Inc. (ZIMV) Q2 2024 Earnings Call Transcript
ZimVie Announces FDA Clearance and U.S. Launch of GenTek® Restorative Components
ZimVie to Report Second Quarter Financial Results on August 1, 2024
ZimVie to Participate in Upcoming Investor Conferences
ZimVie Inc. (ZIMV) Q1 2024 Earnings Call Transcript
ZimVie to Report First Quarter Financial Results on May 8, 2024
ZimVie Announces Closing of Sale of Spine Business
Source: https://incomestatements.info
Category: Stock Reports